Interestingly, by Kaplan-Meier analysis, the projected overall survival (OS) of diagnostic myeloma patients with and without RNF130/miR-340 methylation was 33.3% and 75.0% respectively, and patients with RNF130/miR-340 methylation (n = 15) showed significantly shorter OS than patients without RNF130/miR-340 methylation (n = 48) (Fig. 3c; median 27 vs. 68 months; P = 3.944E−5). Here, RNF130 is linked to plasma cell myeloma.